Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-α expression in the rat uterus

Chad A. Reed, Amy K. Berndtson, Kenneth Nephew

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Tamoxifen, a selective estrogen receptor modulator, has agonist or antagonist activity, depending on the target tissue. The estrogen-like agonist effects of tamoxifen in the uterus are mediated primarily by 4-hydroxytamoxifen (4OH), the major active metabolite. Tamoxifen, 4OH and estradiol-17β (E2) all bind to estrogen receptors (ERα and ERβ), but with different affinities, suggesting that these ligands are capable of producing differential in vivo effects on the uterus. However, differences in short-term effects of tamoxifen, 4OH and E2 on the uterus have not been compared in the rat in vivo. Thus, we treated adult, ovariectomized rats (225-250 g) with vehicle (sesame oil), tamoxifen (1 mg/kg body weight), 4OH (0.01, 0.1 or 1.0 mg/kg body weight), E2 (40 μg/kg body weight), estradiol valerate (a long-lasting estrogen; 40 μg/kg body weight) or ICI 182,780 (a pure anti-estrogen; 1 mg/kg body weight). Animals were sacrificed at 0, 3, 6, 12 or 24 h post-injection, and protein and mRNA levels for ERα and two estrogen-regulated early response genes, c-fos and jun-B, were examined. Administration of E2 and 4OH (1 mg/kg body weight dose) resulted in down-regulation of uterine ERα protein in the uterine luminal and glandular epithelium by 6 h post-treatment. In contrast, no change in ERα level was observed after treatment with tamoxifen. Rapid (by 3h) and transient increases in c-fos and jun-B mRNA levels were observed after E2 treatment; however, c-fos and jun-B induction by 4OH was highly dose dependent, and higher 4OH doses induced rapid but persistent proto-oncogene expression in vivo. Our results demonstrate that tamoxifen and its major metabolite have differential effects on uterine gene expression, and 4OH is highly estrogenic in the rat uterus.

Original languageEnglish
Pages (from-to)559-567
Number of pages9
JournalAnti-Cancer Drugs
Volume16
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Tamoxifen
Estrogen Receptors
Uterus
Body Weight
Estrogens
estradiol valerate
jun Genes
Sesame Oil
fos Genes
Selective Estrogen Receptor Modulators
Messenger RNA
Proto-Oncogenes
afimoxifene
Estradiol
Therapeutics
Down-Regulation
Epithelium
Ligands
Gene Expression
Injections

Keywords

  • Anti-estrogen
  • Breast cancer
  • Estrogen receptor
  • Tamoxifen
  • Uterus

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-α expression in the rat uterus. / Reed, Chad A.; Berndtson, Amy K.; Nephew, Kenneth.

In: Anti-Cancer Drugs, Vol. 16, No. 5, 05.2005, p. 559-567.

Research output: Contribution to journalArticle

@article{38a4b9f46dba478785c7573b1850cb2a,
title = "Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-α expression in the rat uterus",
abstract = "Tamoxifen, a selective estrogen receptor modulator, has agonist or antagonist activity, depending on the target tissue. The estrogen-like agonist effects of tamoxifen in the uterus are mediated primarily by 4-hydroxytamoxifen (4OH), the major active metabolite. Tamoxifen, 4OH and estradiol-17β (E2) all bind to estrogen receptors (ERα and ERβ), but with different affinities, suggesting that these ligands are capable of producing differential in vivo effects on the uterus. However, differences in short-term effects of tamoxifen, 4OH and E2 on the uterus have not been compared in the rat in vivo. Thus, we treated adult, ovariectomized rats (225-250 g) with vehicle (sesame oil), tamoxifen (1 mg/kg body weight), 4OH (0.01, 0.1 or 1.0 mg/kg body weight), E2 (40 μg/kg body weight), estradiol valerate (a long-lasting estrogen; 40 μg/kg body weight) or ICI 182,780 (a pure anti-estrogen; 1 mg/kg body weight). Animals were sacrificed at 0, 3, 6, 12 or 24 h post-injection, and protein and mRNA levels for ERα and two estrogen-regulated early response genes, c-fos and jun-B, were examined. Administration of E2 and 4OH (1 mg/kg body weight dose) resulted in down-regulation of uterine ERα protein in the uterine luminal and glandular epithelium by 6 h post-treatment. In contrast, no change in ERα level was observed after treatment with tamoxifen. Rapid (by 3h) and transient increases in c-fos and jun-B mRNA levels were observed after E2 treatment; however, c-fos and jun-B induction by 4OH was highly dose dependent, and higher 4OH doses induced rapid but persistent proto-oncogene expression in vivo. Our results demonstrate that tamoxifen and its major metabolite have differential effects on uterine gene expression, and 4OH is highly estrogenic in the rat uterus.",
keywords = "Anti-estrogen, Breast cancer, Estrogen receptor, Tamoxifen, Uterus",
author = "Reed, {Chad A.} and Berndtson, {Amy K.} and Kenneth Nephew",
year = "2005",
month = "5",
doi = "10.1097/00001813-200506000-00012",
language = "English",
volume = "16",
pages = "559--567",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-α expression in the rat uterus

AU - Reed, Chad A.

AU - Berndtson, Amy K.

AU - Nephew, Kenneth

PY - 2005/5

Y1 - 2005/5

N2 - Tamoxifen, a selective estrogen receptor modulator, has agonist or antagonist activity, depending on the target tissue. The estrogen-like agonist effects of tamoxifen in the uterus are mediated primarily by 4-hydroxytamoxifen (4OH), the major active metabolite. Tamoxifen, 4OH and estradiol-17β (E2) all bind to estrogen receptors (ERα and ERβ), but with different affinities, suggesting that these ligands are capable of producing differential in vivo effects on the uterus. However, differences in short-term effects of tamoxifen, 4OH and E2 on the uterus have not been compared in the rat in vivo. Thus, we treated adult, ovariectomized rats (225-250 g) with vehicle (sesame oil), tamoxifen (1 mg/kg body weight), 4OH (0.01, 0.1 or 1.0 mg/kg body weight), E2 (40 μg/kg body weight), estradiol valerate (a long-lasting estrogen; 40 μg/kg body weight) or ICI 182,780 (a pure anti-estrogen; 1 mg/kg body weight). Animals were sacrificed at 0, 3, 6, 12 or 24 h post-injection, and protein and mRNA levels for ERα and two estrogen-regulated early response genes, c-fos and jun-B, were examined. Administration of E2 and 4OH (1 mg/kg body weight dose) resulted in down-regulation of uterine ERα protein in the uterine luminal and glandular epithelium by 6 h post-treatment. In contrast, no change in ERα level was observed after treatment with tamoxifen. Rapid (by 3h) and transient increases in c-fos and jun-B mRNA levels were observed after E2 treatment; however, c-fos and jun-B induction by 4OH was highly dose dependent, and higher 4OH doses induced rapid but persistent proto-oncogene expression in vivo. Our results demonstrate that tamoxifen and its major metabolite have differential effects on uterine gene expression, and 4OH is highly estrogenic in the rat uterus.

AB - Tamoxifen, a selective estrogen receptor modulator, has agonist or antagonist activity, depending on the target tissue. The estrogen-like agonist effects of tamoxifen in the uterus are mediated primarily by 4-hydroxytamoxifen (4OH), the major active metabolite. Tamoxifen, 4OH and estradiol-17β (E2) all bind to estrogen receptors (ERα and ERβ), but with different affinities, suggesting that these ligands are capable of producing differential in vivo effects on the uterus. However, differences in short-term effects of tamoxifen, 4OH and E2 on the uterus have not been compared in the rat in vivo. Thus, we treated adult, ovariectomized rats (225-250 g) with vehicle (sesame oil), tamoxifen (1 mg/kg body weight), 4OH (0.01, 0.1 or 1.0 mg/kg body weight), E2 (40 μg/kg body weight), estradiol valerate (a long-lasting estrogen; 40 μg/kg body weight) or ICI 182,780 (a pure anti-estrogen; 1 mg/kg body weight). Animals were sacrificed at 0, 3, 6, 12 or 24 h post-injection, and protein and mRNA levels for ERα and two estrogen-regulated early response genes, c-fos and jun-B, were examined. Administration of E2 and 4OH (1 mg/kg body weight dose) resulted in down-regulation of uterine ERα protein in the uterine luminal and glandular epithelium by 6 h post-treatment. In contrast, no change in ERα level was observed after treatment with tamoxifen. Rapid (by 3h) and transient increases in c-fos and jun-B mRNA levels were observed after E2 treatment; however, c-fos and jun-B induction by 4OH was highly dose dependent, and higher 4OH doses induced rapid but persistent proto-oncogene expression in vivo. Our results demonstrate that tamoxifen and its major metabolite have differential effects on uterine gene expression, and 4OH is highly estrogenic in the rat uterus.

KW - Anti-estrogen

KW - Breast cancer

KW - Estrogen receptor

KW - Tamoxifen

KW - Uterus

UR - http://www.scopus.com/inward/record.url?scp=18844401180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844401180&partnerID=8YFLogxK

U2 - 10.1097/00001813-200506000-00012

DO - 10.1097/00001813-200506000-00012

M3 - Article

VL - 16

SP - 559

EP - 567

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -